Thoenes Martin, Bramlage Peter, Zamorano Pepe, Messika-Zeitoun David, Wendt Daniel, Kasel Markus, Kurucova Jana, Steeds Richard P
Léman Research Institute, Schaffhausen am Rheinfall, Switzerland.
Edwards Lifesciences, Nyon, Switzerland.
J Thorac Dis. 2018 Sep;10(9):5584-5594. doi: 10.21037/jtd.2018.09.02.
In Europe, approximately one million people over 75 years suffer from severe aortic stenosis (AS), one of the most serious and most common valve diseases, and this disease burden is increasing with the aging population. A diagnosis of severe symptomatic AS is associated with an average life expectancy of 2-3 years and necessitates a timely valve intervention. Guidelines for valve replacement therapy have been established but only a proportion of patients with symptomatic AS actually receive this life-saving treatment. The decision for valve intervention in asymptomatic patients with severe AS is often more challenging and likely results in fewer patients receiving treatment in comparison to their symptomatic counterparts. This article reviews the epidemiology and clinical manifestations of AS, the associated economic burden of AS to the healthcare system, the diagnosis of AS and the possible mechanisms for the introduction of routine screening in elderly patients. Elderly patients typically visit healthcare providers more frequently than younger patients, thereby providing increased opportunities for AS screening and this, along with raising patient awareness of the symptoms of AS, has the potential to result in the earlier diagnosis and treatment of AS and increased patient survival.
在欧洲,约有100万75岁以上的人患有严重主动脉瓣狭窄(AS),这是最严重且最常见的瓣膜疾病之一,并且随着人口老龄化,这种疾病负担正在增加。重度症状性AS的诊断与平均2至3年的预期寿命相关,因此需要及时进行瓣膜干预。虽然已经制定了瓣膜置换治疗指南,但实际上只有一部分有症状的AS患者接受了这种挽救生命的治疗。对于无症状的重度AS患者,决定是否进行瓣膜干预往往更具挑战性,与有症状的患者相比,接受治疗的人数可能更少。本文综述了AS的流行病学和临床表现、AS给医疗系统带来的相关经济负担、AS的诊断以及在老年患者中开展常规筛查的可能机制。老年患者通常比年轻患者更频繁地就医,从而为AS筛查提供了更多机会,这与提高患者对AS症状的认识一起,有可能实现AS的早期诊断和治疗,并提高患者生存率。